文献速递免疫规划妇幼与学校卫生

孕期百日咳疫苗接种对妊娠与出生结局的安全性:前瞻性队列研究

Safety of maternal pertussis vaccination on pregnancy and birth outcomes: A prospective cohort study.
PubMed 文献 · Vaccine · 2020-12-19

该前瞻性队列纳入1272名健康初产妇,2015–2018年在南澳两家产科医院随访,80.1%接种了孕期百日咳疫苗。接种者分娩孕周平均延长0.22周(95%CI 0.001,0.44),且未增加绒毛膜羊膜炎、妊娠期高血压、子痫前期、早产、低出生体重、小于胎龄儿及新生儿不良结局风险。

要点

  • 孕期百日咳疫苗接种未增加不良妊娠与出生结局风险。
  • 接种者分娩孕周平均延长0.22周(95%CI 0.001,0.44)。
  • 调整孕期流感疫苗接种后结果无实质性改变。

核心结论

  • 孕期百日咳疫苗接种不增加不良妊娠和出生结局风险,证据令人安心。

研究设计与样本

  • 前瞻性队列研究,纳入1272名健康初产妇,2015–2018年南澳两家产科医院随访。

主要发现

  • 80.1%(n=1019)孕妇接种了孕期百日咳疫苗。
  • 接种者分娩孕周平均延长0.22周(95%CI 0.001,0.44)。
  • 绒毛膜羊膜炎aRR 0.71(95%CI 0.27,1.82),妊娠期高血压aHR 1.24(95%CI 0.66,2.30)。
  • 子痫前期aHR 0.75(95%CI 0.47,1.18),早产aHR 0.99(95%CI 0.47,2.07)。
  • 低出生体重aHR 0.72(95%CI 0.41,1.27),小于胎龄儿aHR 0.67(95%CI 0.29,1.55)。

临床怎么用

  • 研究结果支持孕期接种百日咳疫苗以预防早期婴儿百日咳相关疾病和死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety of maternal pertussis vaccination on pregnancy and birth outcomes. METHODS: The study population comprised 1272 healthy nulliparous pregnant women who participated in Screening Tests to identify poor Outcomes in Pregnancy (STOP) study at two obstetric hospitals in South Australia between 2015 and 2018. Participants were followed prospectively, with vaccination (confirmed by medical records), extensive amounts of pregnancy and birth outcome data collected by research midwives. Adjusted relative risks (aRRs) and hazard ratios (aHRs) were estimated accounting for time-varying vaccine exposure and the temporal nature of each outcome. RESULTS: Of the 1272 women included in this study, 80.1% (n = 1019) received maternal pertussis vaccination. Vaccinated women had an average 0.22 weeks (95% CI 0.001, 0.44) longer gestation at delivery compared to unvaccinated women. Maternal pertussis vaccination was not associated with chorioamnionitis (aRR 0.71, 95% CI 0.27,1.82), gestational hypertension (aHR 1.24, 95% CI, 0.66, 2.30), preeclampsia (aHR 0.75, 95% CI 0.47, 1.18) nor preterm birth (aHR 0.99, 95% CI 0.47, 2.07). Neither risk of low birth weight (aHR 0.72, 95% CI 0.41, 1.27) nor small for gestational age infants (aHR 0.67,95% CI 0.29, 1.55) were increased following maternal pertussis vaccination. No associations between pertussis vaccination during pregnancy and adverse birth outcomes including admission to the neonatal care unit, low Apgar scores, and mechanical ventilation were observed. Results were not materially changed after adjustment for maternal influenza vaccination. CONCLUSION: Our study provides reassuring evidence of the safety of maternal pertussis vaccination with no increased risk of adverse pregnancy and birth outcomes. These findings support recommendations for pertussis vaccination during pregnancy to prevent morbidity and mortality associated with early-infant pertussis disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mohammed H, Roberts CT, Grzeskowiak LE, et al. Safety of maternal pertussis vaccination on pregnancy and birth outcomes: A prospective cohort study. Vaccine. 2020. PMID: 33280854. doi:10.1016/j.vaccine.2020.11.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。